Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

NCT07221513 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

HFrEF - Heart Failure With Reduced Ejection Fraction
HFpEF - Heart Failure With Preserved Ejection Fraction
Group 2 Pulmonary Hypertension

Interventions

DRUG: JK07

Sponsor

Salubris Biotherapeutics Inc